Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02544750 · ClinicalTrials.gov registry record · Phase 3
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 199
- Enrollment target
NCT02544750 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 199 participants.
The verdict
NCT02544750, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 199 participants
- Enrollment target
Study Summary
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.
Interventions
- DRUG GWP42003-P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2021-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02544750
The ClinicalTrials.gov registry entry for NCT02544750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GWP42003-P is the first listed.
NCT02544750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02544750 about?
NCT02544750 is a clinical study titled "An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)". This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's do...
What is the current status of trial NCT02544750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 199 participants. The study started on 2016-08-31. Estimated completion is 2021-06-11.
What interventions are being tested in trial NCT02544750?
The interventions under investigation include: GWP42003-P (DRUG).
Who is sponsoring clinical trial NCT02544750?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.